14 Apr 2025 • Over a median follow-up of 2.3 years, the composite primary endpoint of all-cause death, myocardial infarction (MI), or stroke occurred in 4.4% of the clopidogrel group versus 6.6% with aspirin (HR 0.71).

Clopidogrel reduced the risk of MI by nearly half (HR 0.54) and showed a trend toward lower mortality (HR 0.71), with no difference in bleeding rates between groups.

These findings suggest that for high-risk patients post-percutaneous coronary intervention (PCI), clopidogrel may be a safer and more effective long-term antiplatelet monotherapy option than aspirin.

Source: The Lancet | Read Full Story